Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Direct Meds

Two GLP-1 desks, one scoreboard. We put Eden and Direct Meds head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 2 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 28 · Grade B−

Direct Meds

Visit Direct Meds Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 82 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Direct Meds a bad call — it's best for readers who want a needle-free oral or sublingual route on either molecule and an all-inclusive price with no separate membership — and who are comfortable that the figures are company-stated rather than checkout-verified. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
80
Supply Reliability
92
80
Transparency
93
78
Access Breadth
90
84
Clinical Oversight
92
83
Track Record
89
78
EdenBrief Score 91 · 82Direct Meds

Price, coverage & the tracker

EdenDirect Meds
Brief Score91/100 (A−)82/100 (B−)
Semaglutide$239/mo$179/mo
Tirzepatide$349/mo$224/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Direct Meds: Company-stated rates unchanged this cycle — but we price these off the desk's own listings, not a live-verified checkout, so treat them as indicative.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.